Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
CHU de Bordeaux, Bordeaux, France
Contact: Principal Investigator (Jean-Frédéric BLANC, Professor)AP-HP Hôpital Beaujon, Clichy, France
Contact: Principal Investigator (Mohamed BOUATTOUR, Doctor)Centre Georges Francois Leclerc, Dijon, France
Contact: Principal Investigator (Francois GHIRINGHELLI, Professor)Hôpital Saint Joseph, Marseille, France
Contact: Study coordinator (Xavier Adhoute) · xadhoute@hopital-saint-joseph.fr · +33 (0) 4 91 80 82 35CHU de Montpellier, Montpellier, France
Contact: Principal Investigator (Boris GUIU, Professor)CHU Hôtel-Dieu, Nantes, France
Contact: Principal Investigator (Yann TOUCHEFEU, Professor)AP-HP Hôpital Cochin, Paris, France
Contact: Principal Investigator (Anais VALLET-PICHARD, Doctor)CHU de Poitiers, Poitiers, France
Contact: Study coordinator (Marielle DUBREUIL) · marielle.dubreuil@chu-poitiers.fr · +33 5 16 60 42 34Contact: Principal Investigator (Amina LARBI, Doctor)Centre Eugene Marquis, Rennes, France
Contact: Principal Investigator (Julien EDELINE, Professor)CHRU de Strasbourg, Strasbourg, France
Contact: Study coordinator (Hakim TAYEBI) · Delegation_recherche@chru-strasbourg.fr · +33 3 88 11 51 58Contact: Principal Investigator (Antonio SAVIANO, Doctor)CHU de Rangueil, Toulouse, France
Contact: Principal Investigator (Jean-Marie PERON, Professor)
Study leads
Julien EDELINE, Professor
Principal Investigator
Centre Eugène Marquis
Laure Monard
Study Director
UNICANCER